[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605620":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":36,"responsibleParty":53,"collaborators":26,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":26,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":26,"enrollmentInfo":66,"targetDuration":26,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":26,"overallStatus":39,"whyStopped":26,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Capital Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experiment","EXPERIMENTAL","RAPART technology",[13],"Radiation: Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology（RAPART)）",{"label":15,"type":16,"description":17,"interventionNames":18},"conventional radiotherapy","ACTIVE_COMPARATOR","conventional radiotherapy 2Gy\u002FF",[19],"Radiation: Conventional radiotherapy",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"RADIATION","Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology（RAPART)）","RAPART technology is a special combination of ART and RAPRT, with a total course limit of no more than 30 exposures. The entire course of treatment can be divided into two stages: the first stage is completely the same as the conventional radiotherapy group, with a total of 23 doses of 2 Gy per session. The second stage is the combination of ART and PAPRT. ART uses a CT or PET\u002FCT localization simulation to be performed again during the course of treatment (usually after completing the first part of 17-19 exposures) to generate a new adaptive plan, and after completing the first stage of 23 exposures, treatment is carried out according to the new adaptive plan. RAPAT uses ERCC1\u002F2 biomarkers to predict the patient's radiation sensitivity and determine individualized radiation dose accordingly. ERCC1\u002F2 biomarkers divided patients into 5 different radiosensitivity groups, corresponding to 5 different radiation doses (74, 66, 62, 54, and 50 Gy).",[9],null,{"type":22,"name":28,"description":15,"armGroupLabels":29,"otherNames":26},"Conventional radiotherapy",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Feng-Ming (Spring) Kong","CONTACT","+86 188 0755 0703","kong0001@hku.hk",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"University of Hong Kong Shenzhen Hospital","RECRUITING","Shenzhen","Guangdong","518000","China","CN",{"type":46,"coordinates":47},"Point",[48,49],114.0683,22.54554,{"lat":49,"lon":48},[52],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Jin jianyue","Professor","100605620","rapart-in-locally-advanced-non-small-cell-lung-cancer-patients-100605620",false,"NCT07164885","RAPART in Locally Advanced Non-small Cell Lung Cancer Patients","Phase II\u002FIII Randomized Clinical Trial of Radiosensitivity-Assisted Personalized Adaptive RadioTherapy (RAPART) in Locally Advanced Non-small Cell Lung Cancer Patients","Inclusion Criteria:\n\n* Adult research participants, aged over 18 years old;\n* Non small cell lung cancer that requires pathological confirmation;\n* All stage 3 unresectable non-small cell lung cancer, including stage correction after MDT and stage downgrading after treatment (4 → 3), and stage upregulation due to disease progression (2 → 3);\n* ECOG physical condition is 0-2;\n* In addition to study participants who have not received any treatment, study participants who have undergone surgery, chemotherapy, immunotherapy, and targeted therapy are also eligible for enrollment.\n\nExclusion Criteria:\n\n* Prisoners who are not convenient for close clinical follow-up;\n* Study participants with contraindications to radiation therapy.","ALL","18 Years",{"count":67,"type":68},911,"ESTIMATED","INTERVENTIONAL",[71],"NA","This is a Phase II\u002FIII randomized clinical trial of Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology (RAPART) in locally advanced non-small cell lung cancer patients. The main objective is to test the overall improvement of overall survival (OS), progression free survival (PFS), and local progression free survival (LPFS) of unresectable stage III NSCLC under standard and non-standard mixed treatment conditions compared to conventional 60Gy radiotherapy.",[74],"Locally Advanced Non-small Cell Lung Cancer","2025-12-01",{"date":77,"type":78},"2025-12-02","ACTUAL",{"date":80,"type":78},"2025-02-17",{"date":82,"type":68},"2027-12-30",{"name":5,"class":6},1]